Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
83.90
+0.19 (0.23%)
NASDAQ· Last Trade: Jul 15th, 7:33 PM EDT
Detailed Quote
Previous Close
83.71
Open
83.77
Bid
83.85
Ask
84.00
Day's Range
83.74 - 84.00
52 Week Range
25.83 - 84.00
Volume
3,552,692
Market Cap
4.53B
PE Ratio (TTM)
-16.98
EPS (TTM)
-4.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
7,430,978
Chart
About Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)
Crinetics Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases and disorders. The company leverages its expertise in the field of endocrine science to discover and create targeted treatments that address unmet medical needs. Crinetics aims to provide effective solutions for patients suffering from conditions related to hormonal imbalances by advancing its pipeline of novel compounds through various stages of clinical development. Through its commitment to research and development, the company strives to enhance the quality of life for individuals affected by complex endocrine issues. Read More
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Crinetics Pharmaceuticals (NASDAQ:CRNX) has outperformed the market over the past 5 years by 21.74% on an annualized basis producing an average annual return of 33.07%. Currently, Crinetics Pharmaceuticals has a market
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion. Tvardi Therapeutics (NASDAQ:TVRD)
Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion. Bluejay Diagnostics
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash.
Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-market session. Crinetics Pharmaceuticals (NASDAQ:CRNX) stock moved upwards by 99.85% to $84.0. The company's
